Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01429168
A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
Completed
- Conditions
- DyslipidemiaHypercholesterolemia
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3215
- Registration Number
- NCT01414192
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 472
- Registration Number
- NCT01408615
A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
Completed
- Conditions
- Hypertension
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 136
- Registration Number
- NCT01390415
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
Phase 3
Completed
- Conditions
- Nasal Polyps
- Interventions
- Drug: Placebo for MFNSDrug: Mometasone Furoate Nasal Spray (MFNS)
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 748
- Registration Number
- NCT01386125
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1682
- Registration Number
- NCT01381679
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Ezetimibe/atorvastatinDrug: AtorvastatinDrug: Placebo to atorvastatinDrug: EzetimibeDrug: Placebo to ezetimibe/atorvastatinDrug: Placebo to ezetimibe
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 328
- Registration Number
- NCT01370603
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Ezetimibe/atorvastatinDrug: AtorvastatinDrug: Placebo to atorvastatinDrug: EzetimibeDrug: Placebo to ezetimibe/atorvastatinDrug: Placebo to ezetimibe
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 406
- Registration Number
- NCT01370590
Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
Completed
- Conditions
- Hypertension
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1705
- Registration Number
- NCT01368185
A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
Phase 4
Completed
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Drug: alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)Drug: CalcitriolDietary Supplement: Calcium 500 mg
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 219
- Registration Number
- NCT01350934
© Copyright 2025. All Rights Reserved by MedPath